Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Grace Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 15 | 17 | +2 |
| Shares | 2.09M | 4.02M | +1.94M (+92.7%) |
| Value | $7.84M | $9.17M | +$1.33M (+17.0%) |
New holders (3)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 1,178,203 | $2.69M | 0.22% |
| Stonepine Capital Management, LLC | 294,550 | $665.7K | 0.77% |
| Palumbo Wealth Management LLC | 46,007 | $104.9K | 0.04% |
Sold out (1)
Institutions that held Grace Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Golden State Wealth Management, LLC | 31 | $116 |